Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients
Authors:
- Aslıhan Avanoğlu GÜLERAGAslıhan Avanoğlu GÜLER
- Büşra Özçi̇mEnBÖBüşra Özçi̇mEn
- Mesude Seda AydoğduMAMesude Seda Aydoğdu
- Alper SariASAlper Sari
- Aliyeva NumuneANAliyeva Numune
- Nazife Tüzün ErsanNENazife Tüzün Ersan
- Seda ÇolakSÇSeda Çolak
- Hazan Karadeni̇zHKHazan Karadeni̇z
- Hamit KüçükHKHamit Küçük
- Yasemin YalçinkayaYYYasemin Yalçinkaya
- Abdulsamet ErdenAEAbdulsamet Erden
Open Access
- 1 January 2024
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (1) , 76-85
Abstract
The objective of this study is to evaluate the clinical presentations and adverse outcomes of Coronavirus Disease 2019 (COVID-19) in patients with systemic sclerosis (SSc) and assess the impact of SSc features on the clinical course of COVID-19.Materials and methods: In this multicenter, retrospective study, SSc patients with COVID-19 were included. Clinical features of SSc, along with detailed COVID-19 data, were extracted from medical records and patient interviews.Results: The study included 112 patients (mean age 51.4 ± 12.8 years; 90.2% female). SSc-associated interstitial lung disease (ILD) was evident in 57.1% of the patients. The findings revealed hospitalization in 25.5%, respiratory support in 16.3%, intensive care unit admission in 3.6%, and a mortality rate of 2.7% among SSc patients with COVID-19. Risk factors for respiratory failure, identified through univariate analysis, included ILD (OR: 7.49, 95% CI: 1.63–34.46), ≥1 comorbidity (OR: 4.55, 95% CI: 1.39–14.88), a higher physician global assessment score at the last outpatient visit (OR 2.73, 95% CI: 1.22–6.10), and the use of mycophenolate at the time of infection (OR: 5.16, 95 %CI: 1.79–14.99). Notably, ≥1 comorbidity emerged as the sole significant predictor of the need for respiratory support in COVID-19 (OR: 5.78, 95% CI: 1.14–29.23). In the early post-COVID-19 period, 17% of patients reported the progression of the Raynaud phenomenon, and 10.6% developed new digital ulcers. Furthermore, progression or new onset of dyspnea and cough were detected in 28.3% and 11.4% of patients, respectively.Conclusion: This study suggests a potential association between adverse outcomes of COVID-19 and SSc-related ILD, severe disease activity, and the use of mycophenolate. Additionally, it highlights that having comorbidities is an independent risk factor for the need for respiratory support in COVID-19 cases.Keywords
This publication has 32 references indexed in Scilit:
- Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysisAging, 2020
- Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary PathologistsVirchows Archiv, 2020
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals of the Rheumatic Diseases, 2020
- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreakJournal of Autoimmunity, 2020
- Pathophysiology of systemic sclerosis: current understanding and new insightsExpert Review of Clinical Immunology, 2019
- Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort studyClinical Rheumatology, 2018
- Analysis of length of hospital stay using electronic health records: A statistical and data mining approachPLOS ONE, 2018
- Epstein–Barr Virus Infection Induces Aberrant TLR Activation Pathway and Fibroblast–Myofibroblast Conversion in SclerodermaJournal of Investigative Dermatology, 2014
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010
- Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases.2006